Last reviewed: July 21, 2026

Last updated: July 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

"TRT Nation Retatrutide" refers to retatrutide (research code LY3437943), an investigational triple GLP-1/GIP/glucagon receptor agonist from Eli Lilly. The most important fact for anyone comparing it to available treatments: retatrutide is not FDA-approved and not legally available for prescription or purchase as of July 2026, whether marketed under a vendor name or not. It is still in the Phase 3 TRIUMPH program, with the earliest realistic approval window in 2027. Any site selling "TRT Nation retatrutide" or a "research use only" vial is operating outside the regulatory framework, and the FDA has issued consumer warnings about these products. PlexusDx does not sell, prescribe, or recommend retatrutide. This article explains the triple-agonist mechanism, what the actual trial data show, and the compounded GLP-1 options available today.

What the triple-agonist mechanism is — and how it differs from dual agonists

Retatrutide activates three receptors at once: GLP-1 (appetite suppression and insulin response), GIP (insulin response and adipose handling, the receptor tirzepatide adds on top of GLP-1), and glucagon (energy expenditure and hepatic fat metabolism). This differs from dual agonists like tirzepatide, which activate GLP-1 and GIP only. The theoretical advantage of adding glucagon activity is greater energy expenditure and liver-fat reduction. Because no FDA-approved obesity drug currently activates the glucagon receptor, retatrutide's long-term safety will need its own evidence base rather than borrowing from the established GLP-1 class — which is one reason it is still in trials rather than on the market.

What the retatrutide trial data actually show

Retatrutide's evidence comes from the TRIUMPH Phase 3 program and the earlier Phase 2 trial — not from "SUMMIT" trials, which are tirzepatide studies. The Phase 2 trial (Jastreboff et al., NEJM 2023) reported roughly 24.2% mean body-weight loss at 48 weeks on the 12 mg dose. Eli Lilly's December 2025 TRIUMPH-4 topline release reported approximately 28.7% mean body-weight loss over 68 weeks at 12 mg — among the largest averages reported in any Phase 3 obesity trial — though that readout was in a knee-osteoarthritis population, so the broader TRIUMPH-1 result is still pending. Discontinuation rates trended higher than with semaglutide or tirzepatide, and TRIUMPH-4 flagged a dysesthesia signal (abnormal skin sensations) in up to roughly 21% of participants on 12 mg versus about 0.7% on placebo. Because retatrutide is not marketed, there is no post-marketing or real-world safety surveillance data — only clinical-trial data collected under study conditions.

Triple-agonist vs dual-agonist vs monotherapy — how the classes compare

Only two of these three classes are available outside a clinical trial right now: single-agonist semaglutide and dual-agonist tirzepatide. The table frames typical trial weight-loss ranges by mechanism tier. Treat these as class-level context from separate trials, not head-to-head results, and remember that average trial weight loss does not predict any individual's response.

Factor Monotherapy (GLP-1 only) Dual-Agonist (GLP-1/GIP) Triple-Agonist (GLP-1/GIP/glucagon)
Receptor Targets GLP-1R only GLP-1R + GIPR GLP-1R + GIPR + glucagon
Trial Weight Loss (highest dose) ~15% (semaglutide, STEP 1) ~22.5% (tirzepatide, SURMOUNT-1) ~28.7% (retatrutide 12 mg, TRIUMPH-4)
Availability (July 2026) Available (branded + compounded) Available (branded + compounded) Investigational — not available
Notable Tolerability Notes Dose-dependent nausea GI symptoms; years of post-market experience Higher discontinuation; dysesthesia signal in trials

Available compounded alternatives through PlexusDx

If you want an available treatment rather than a pipeline drug, PlexusDx compounds the two mechanism classes with the most clinical evidence through licensed 503A pharmacies. Tirzepatide Injection ($289/mo) is the GIP/GLP-1 dual agonist that covers two of the three receptors retatrutide targets, with established post-market experience. Semaglutide Injection ($189/mo) is the single-agonist option. GLP-Squared ($289/mo) stacks compounded semaglutide and tirzepatide. All are all-inclusive, cash-pay, no membership, available in all 50 states, and are pharmacy-prepared formulations — not FDA-approved finished drug products.

Genetic context for GLP-1 pathway response

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to retatrutide or any specific medication, and it does not determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is "TRT Nation retatrutide" available to buy or prescribe?

No. Retatrutide is investigational and not FDA-approved, regardless of any vendor name attached to it. It cannot be legally prescribed, dispensed, or compounded, and the FDA has warned against "research use only" retatrutide products. PlexusDx does not distribute branded or compounded retatrutide.

How much weight loss did retatrutide produce in trials?

In the TRIUMPH-4 Phase 3 trial, the 12 mg dose produced approximately 28.7% mean body-weight loss over 68 weeks in a knee-osteoarthritis population. The broader obesity trial (TRIUMPH-1) has not yet reported. Individual results vary, and average trial weight loss does not predict your response.

Which trials support retatrutide — is it SUMMIT?

No. Retatrutide's evidence comes from the Phase 2 trial (NEJM 2023) and the Phase 3 TRIUMPH program. SUMMIT refers to tirzepatide studies, not retatrutide. There is no post-marketing safety data for retatrutide because it is not on the market.

Is a dual agonist like tirzepatide a reasonable option while retatrutide is unavailable?

Tirzepatide activates two of the three receptors retatrutide targets (GIP and GLP-1) and has years of post-market clinical experience. PlexusDx's Tirzepatide Injection ($289/mo) or GLP-Squared ($289/mo) are the closest currently-available analogues. Discuss any GLP-1 decision with a licensed clinician.

What does the Precision Peptide Genetic Test reveal?

It identifies variants in GLP1R, GIPR, FTO, and MC4R that relate to GLP-1/GIP pathway biology. Results do not predict your response to any specific medication; they give you and your provider pathway-level context to support a more personalized conversation.

Related Reading

Disclaimer: This article is educational and is not medical advice. Retatrutide is investigational and not FDA-approved as of July 2026; PlexusDx does not sell, prescribe, or recommend it. PlexusDx offers compounded semaglutide and tirzepatide through its Weight Management Protocols; these are not FDA-approved finished drug products. Consult a licensed clinician before starting any medication.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves